BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...across NVS in gene and cell therapy” as well, said Knudten, referring to AVXS-201 and AVXS-301...
BioCentury | Mar 3, 2008
Clinical News

Apricitabine: Phase IIb/III ongoing

Avexa began the Phase III portion of a double-blind, international Phase IIb/III (AVX-301) trial comparing 800 and 1,200 mg of oral apricitabine given twice daily vs. 150 mg of oral lamivudine ( 3TC ) given twice daily...
Items per page:
1 - 2 of 2